These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 31781100)

  • 1. IgA and IgG1 Specific to Vi Polysaccharide of
    Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
    Front Immunol; 2019; 10():2582. PubMed ID: 31781100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
    Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
    Front Immunol; 2020; 11():574057. PubMed ID: 33424833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
    Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
    Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
    Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vi-specific serological correlates of protection for typhoid fever.
    Jin C; Hill J; Gunn BM; Yu WH; Dahora LC; Jones E; Johnson M; Gibani MM; Spreng RL; Alam SM; Nebykova A; Juel HB; Dennison SM; Seaton KE; Fallon JK; Tomaras GD; Alter G; Pollard AJ
    J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33180929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for preventing typhoid fever.
    Milligan R; Paul M; Richardson M; Neuberger A
    Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
    Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
    Kantele A; Pakkanen SH; Karttunen R; Kantele JM
    PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
    N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies.
    Gibani MM; Voysey M; Jin C; Jones C; Thomaides-Brears H; Jones E; Baker P; Morgan M; Simmons A; Gordon MA; Cerundolo V; Pitzer VE; Angus B; Levine MM; Darton TC; Pollard AJ
    Clin Infect Dis; 2019 Apr; 68(8):1265-1273. PubMed ID: 30252031
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Dahora LC; Verheul MK; Williams KL; Jin C; Stockdale L; Cavet G; Giladi E; Hill J; Kim D; Leung Y; Bobay BG; Spicer LD; Sawant S; Rijpkema S; Dennison SM; Alam SM; Pollard AJ; Tomaras GD
    Sci Immunol; 2021 Oct; 6(64):eabj1181. PubMed ID: 34714686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
    Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
    Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC; Jones C; Blohmke CJ; Waddington CS; Zhou L; Peters A; Haworth K; Sie R; Green CA; Jeppesen CA; Moore M; Thompson BA; John T; Kingsley RA; Yu LM; Voysey M; Hindle Z; Lockhart S; Sztein MB; Dougan G; Angus B; Levine MM; Pollard AJ
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004926. PubMed ID: 27533046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.